FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to focus on safety concerns in the decisive meeting.
Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
